Activist investors are trying again to seize control of 'Pharma Bro' Martin Shkreli's biotech company, according to a report
Reuters
- Activist investors want to seize Shkreli's 44% stake in Phoenixus, The New York Post reported.
- They failed to replace its board of directors Monday after Shkreli voted against the move from prison.
- Shkreli infamously hiked up the price of life-saving drug Daraprim by 5,000% in 2015.
- See more stories on Insider's business page.
Activist investors are attempting to seize control of "Pharma Bro" Martin Shkreli's 44% stake in Phoenixus, his controversial biotech company, The New York Post reported.
It comes after the investors failed to replace the Phoenixus board of directors earlier this week, when Shkreli used his sizeable stake to vote against the move from prison.
Shkreli became know as the "Pharma Bro" in 2015 after he hiked up the price of Vyera's life-saving toxoplasmosis drug Daraprim from $13.50 to $750 per pill, leading to the Federal Trade Commission and New York Attorney General Letitia James to sue Shkreli and others in an antitrust case.
In an unrelated matter, Shkreli is currently serving a seven-year sentence for defrauding investors of $10 million when he managed a hedge fund. He is not up for release until late 2023.
Shkreli forfeited his Phoenixus shares after being convicted of fraud but they have not been reassigned, meaning that he is still able to use them to vote from his jail cell. The activist investors are now trying to convince a federal judge in Brooklyn to reassign Shkreli's forfeited shares, the Post reported.
Former Shkreli ally Kevin Mulleady and pharmaceutical industry activist investor Jason Aryeh asked Phoenixus shareholders at a meeting Monday to replace the existing board of directors and proposed a slate of six new directors, as part of a plan to end to Shkreli's influence, The Post reported.
"Martin Shkreli is a blight on this industry," Aryeh told The New York Times last week.
Vyera did not immediately respond to Insider's request for comment.
from Business Insider https://ift.tt/3B58JHP
No comments